- How (Un-)Certain Is (Un-)Safe? Quantifying Uncertainty in the Era of NAMs and NGRA
-
Stars at Night Ballroom B4‚ Convention Center
Chair: Daniele Wikoff, ToxStrategies LLC
Co-Chair: Matthias Herzler, Bundesinstitut für Risikobewertung (BfR), Germany
Primary Endorser: Regulatory and Safety Evaluation Specialty Section
Endorser(s): In Vitro and Alternative Methods Specialty Section
Endorser(s): Risk Assessment Specialty SectionAdvances in mechanistic toxicology, computational modeling, and new approach methodologies (NAMs) are transforming the type of evidence available for chemical safety assessment, driving a transition away from reliance on traditional risk assessment methods dependent towards next-generation risk assessment (NGRA).
A central question for regulators and stakeholders is how confidence can be established in NAM-based assessments while ensuring equal or greater levels of health and environment protection. Although uncertainty has long been recognized in traditional toxicology, current approaches often rely on qualitative descriptions that lack consistency, transparency, and quantitative rigor. Many uncertainty factors historically developed for animal studies may not directly apply to NAM-derived evidence. Conversely, NAMs introduce different sources of uncertainty related to mechanistic interpretation, model structure, biological relevance, toxicokinetics, toxicodynamics, and data integration. As a result, decisions based on NGRA increasingly depend on integrating diverse evidence streams, study types, and levels of biological complexity creating new challenges for decision-makers.
The session will present emerging approaches for probabilistic and integrative uncertainty assessment capable of combining multiple evidence streams and explicitly quantifying the contribution of assumptions, data gaps, and model uncertainty. Case studies will demonstrate approaches to quantify uncertainty as well as how uncertainty analysis can identify the most influential inputs in NAM-based risk assessment. This will include regulatory applications for systemic endpoints, thus expanding discussion beyond endpoints (e.g., skin sensitization) that have defined testing approaches to outcomes involving less biological understanding.
Speakers from different sectors will provide perspectives on quantitatively assessing uncertainty in NAM-based assessments. Concluding remarks will target opportunities to increase confidence and accelerate the implementation of NAMs in chemical safety assessment.
Session and Activity Type
Enter Note
Go to previous page in this tab
Event
